The use of arrays in preimplantation genetic diagnosis and screening

详细信息    查看全文

• 作者：Joyce C. Harper ; Gary Harton
• 关键词：PGD ; PGS ; CGH ; array CGH ; SNP arrays ; mosaicism ; embryo biopsy ; ART
• 刊名：Fertility and Sterility
• 出版年：2010
• 出版时间：September 2010
• 年：2010
• 卷：94
• 期：4
• 页码：1173-1177
• 全文大小：258 K

文摘

Background

In preimplantation genetic diagnosis (PGD), polymerase chain reaction has been used to detect monogenic disorders, and in PGD/preimplantation genetic screening (PGS), fluorescence in situ hybridization (FISH) has been used to analyze chromosomes. Ten randomized controlled trials (RCTs) using FISH-based PGS on cleavage-stage embryos and one on blastocyst-stage embryos have shown that PGS does not increase delivery rates. Is the failure of PGS due to a fundamental flaw in the idea, or are the techniques that are being used unable to overcome their own, inherent flaws? Array-based technology allows for analysis of all of the chromosomes. Two types of arrays are being developed for use in PGD; array comparative genomic hybridization (aCGH) and single nucleotide polymorphism–based (SNP) arrays. Each array can determine the number of chromosomes, however, SNP-based arrays can also be used to haplotype the sample.

Objective(s)

To describe aCGH and SNP array technology and make suggestions for the future use of arrays in PGD and PGS.

Conclusion(s)

If array-based testing is going to prove useful, three steps need to be taken: [1] Validation of the array platform on appropriate cell and tissue samples to allow for reliable testing, even at the single-cell level; [2] deciding which embryo stage is the best for biopsy: polar body, cleavage, or blastocyst stage; [3] performing RCTs to show improvement in delivery rates. If RCTs are able to show that array-based testing at the optimal stage for embryo biopsy increases delivery rates, this will be a major step forward for assisted reproductive technology patients around the world.